FIELD: pharmaceutics.
SUBSTANCE: invention relates to compositions of imaging agent containing radioactive isotope 18F labelled cMet-binding peptides, suitable for imaging in vivo using ositron emission tomography (PET).
EFFECT: there are also described pharmaceutical compositions, methods of producing compositions, as well as methods of imaging in vivo using said compositions for use in cancer therapy.
12 cl, 1 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MARKED PEPTIDES BINDING HEPATOCYTE GROWTH FACTOR (HGF) FOR VISUALISATION | 2008 |
|
RU2473361C9 |
| COMPOSITION FOR OPTICAL VISUALIZATION, METHOD OF ITS PRODUCTION AND USE | 2019 |
|
RU2802481C2 |
| OPTICAL VISUALISATION AGENTS | 2008 |
|
RU2484111C9 |
| VISUALISATION TECHNIQUE | 2008 |
|
RU2505316C2 |
| CONTRAST AGENT AIMED AT UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR | 2005 |
|
RU2394837C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
| SYNTHESIS OF LIXISENATIDE WITH CAPPING | 2019 |
|
RU2782772C2 |
| THERAPEUTIC GUIDANCE AND/OR MONITORING THERAPY FOR TREATING SHOCK | 2020 |
|
RU2835616C1 |
